Michael O. Thorner | Academic Influence

Michael O. Thorner's AcademicInfluence.com Rankings

Michael O. Thorner

Computer Science

#4138

World Rank

#4354

Historical Rank

Machine Learning

#721

World Rank

#731

Historical Rank

Artificial Intelligence

#924

World Rank

#941

Historical Rank

Database

#1367

World Rank

#1439

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Michael O. Thorner's Degrees

PhD Computer Science Stanford University
Masters Computer Science Stanford University
Bachelors Computer Science Stanford University

Similar Degrees You Can Earn

Why Is Michael O. Thorner Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Michael O. Thorner is David C. Harrison Professor Emeritus of Internal Medicine at the University of Virginia specializing in endocrinology and metabolism. He was previously the chief of the division of endocrinology and metabolism and the chair of the department of internal medicine.

(See a Problem?)

Michael O. Thorner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour (1982) (1061)
Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. (1987) (941)
Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. (1998) (675)
Modulation of mammalian life span by the short isoform of p53. (2004) (598)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist (2001) (591)
Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. (1974) (555)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. (2000) (499)
Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. (1988) (476)
Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. (1984) (408)
Ghrelin (2015) (371)
Absence of ghrelin protects against early-onset obesity. (2005) (367)
Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. (1982) (348)
Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. (1990) (335)
Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas: Results of a Prospective Multicenter Study* (1985) (314)
Long-term Treatment of Galactorrhoea and Hypogonadism with Bromocriptine (1974) (312)
Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. (1992) (277)
Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. (2008) (274)
Acyl and total ghrelin are suppressed strongly by ingested proteins, weakly by lipids, and biphasically by carbohydrates. (2008) (273)
Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. (1996) (271)
HUMAN PANCREATIC GROWTH-HORMONE-RELEASING FACTOR SELECTIVELY STIMULATES GROWTH-HORMONE SECRETION IN MAN (1983) (270)
Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. (1992) (260)
Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study. (1984) (256)
Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. (2011) (254)
Novel ghrelin assays provide evidence for independent regulation of ghrelin acylation and secretion in healthy young men. (2008) (246)
The use of anthropometric and dual-energy X-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women. (1999) (241)
Rapid regression of pituitary prolactinomas during bromocriptine treatment. (1980) (235)
Thirty-second sampling of plasma growth hormone in man: correlation with sleep stages. (1991) (233)
Long-term treatment of acromegaly with bromocriptine. (1977) (227)
Consensus statement: medical management of acromegaly. (2005) (227)
Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone. (1979) (222)
A quantitative estimation of growth hormone secretion in normal man: reproducibility and relation to sleep and time of day. (1992) (216)
Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. (2008) (215)
Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. (1994) (213)
Drugs five years later. Bromocriptine. (1984) (213)
Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. (1995) (201)
Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. (1994) (199)
Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine. (1980) (197)
Both oral and transdermal estrogen increase growth hormone release in postmenopausal women--a clinical research center study. (1996) (197)
A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. (1993) (193)
Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion. (1985) (187)
Altered neuroendocrine regulation of gonadotropin secretion in women distance runners. (1985) (181)
GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults (2015) (178)
Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. (1993) (176)
Pulsatile growth hormone release in normal women during the menstrual cycle (1992) (175)
Presence of Human Prolactin-Producing Adenomas and Bromocriptine: A Histological, Immunocytochemical, Ultrastructural, and Morphometric Study (1982) (174)
DOPAMINE IS AN IMPORTANT NEUROTRANSMITTER IN THE AUTONOMIC NERVOUS SYSTEM (1975) (174)
Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. (2001) (171)
Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. (1981) (169)
Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. (2004) (168)
EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY (1983) (165)
REDUCTION OF PITUITARY-TUMOUR SIZE IN PATIENTS WITH PROLACTINOMAS AND ACROMEGALY TREATED WITH BROMOCRIPTINE WITH OR WITHOUT RADIOTHERAPY (1979) (162)
Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. (2007) (159)
Primary hypophysitis: a single-center experience in 16 cases. (2004) (158)
Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. (2001) (158)
Validity of methods of body composition assessment in young and older men and women. (1999) (156)
Bromocriptine treatment of acromegaly. (1975) (154)
Half-time of endogenous growth hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone and suppression with somatostatin. (1989) (152)
Sleep-promoting effects of growth hormone-releasing hormone in normal men. (1993) (151)
Acceleration of growth in two children treated with human growth hormone-releasing factor. (1985) (151)
Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. (1975) (150)
Calcium rather than cyclic AMP as the physiological intracellular regulator of prolactin release. (1980) (149)
Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults (2008) (148)
Spontaneous oscillations of intracellular calcium and growth hormone secretion. (1988) (145)
Temporal structure of in vivo growth hormone secretory events in humans. (1991) (145)
Growth Hormone Release Inhibiting Hormone in Acromegaly (1974) (145)
Normal control of growth hormone secretion. (1993) (144)
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. (2010) (141)
D-Chiro-Inositol Glycans in Insulin Signaling and Insulin Resistance (2010) (138)
The effects of vertical sleeve gastrectomy in rodents are ghrelin independent. (2013) (137)
A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic admknistration of bromocriptine. (1980) (135)
Intracellular calcium concentration and growth hormone secretion in individual somatotropes: effects of growth hormone-releasing factor and somatostatin. (1988) (131)
Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. (1990) (130)
Extrahypothalamic growth-hormone-releasing factor (GRF) secretion is a rare cause of acromegaly: plasma GRF levels in 177 acromegalic patients. (1984) (126)
Ghrelin mimics fasting to enhance human hedonic, orbitofrontal cortex, and hippocampal responses to food. (2014) (122)
Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. (1984) (122)
Hormone pulsatility discrimination via coarse and short time sampling. (1999) (117)
Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. (1996) (116)
Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. (1993) (114)
Bromocriptine treatment of female infertility: report of 13 pregnancies. (1975) (113)
The Case for Initial Surgical Removal of Certain Prolactinomas (1997) (113)
Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. (1999) (112)
Enumeration of lactotropes and somatotropes among male and female pituitary cells in culture: evidence in favor of a mammosomatotrope subpopulation in the rat. (1985) (112)
Management of prolactinomas. (1997) (110)
Serum cortisol response to transsphenoidal surgery for Cushing disease. (2001) (110)
Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumor. (1982) (106)
Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. (2002) (104)
Characterization of a 40 residue peptide from a human pancreatic tumor with growth hormone releasing activity. (1982) (103)
Growth hormone replacement therapy for adults: into the new millennium. (2002) (102)
Amplitude suppression of the pulsatile mode of immunoradiometric luteinizing hormone release in fasting-induced hypoandrogenemia in normal men. (1993) (100)
Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations (2016) (98)
Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. (1985) (97)
Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men. (1998) (96)
Stimulation of growth hormone (GH) and somatomedin C in idiopathic GH-deficient subjects by intermittent pulsatile administration of synthetic human pancreatic tumor GH-releasing factor. (1984) (92)
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. (2003) (91)
INHIBITION OF THE PLASMA-ALDOSTERONE RESPONSE TO FRUSEMIDE BY BROMOCRIPTINE (1975) (91)
Prolactin : basic and clinical correlates (1985) (91)
Evidence for acyl-ghrelin modulation of growth hormone release in the fed state. (2008) (90)
THE EFFECTS OF DOPAMINE, BROMOCRIPTINE, LERGOTRILE AND METOCLOPRAMIDE ON PROLACTIN RELEASE FROM CONTINUOUSLY PERFUSED COLUMNS OF ISOLATED RAT PITUITARY CELLS (1979) (88)
LEAP2 changes with body mass and food intake in humans and mice. (2019) (87)
Rapid sequential intravenous administration of four hypothalamic releasing hormones as a combined anterior pituitary function test in normal subjects. (1985) (87)
Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man. (1987) (85)
Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior. (1997) (85)
Growth hormone and erythropoietin differentially activate DNA-binding proteins by tyrosine phosphorylation (1994) (83)
Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. (1997) (83)
Short-term adult exposure to estradiol feminizes the male pattern of spontaneous and growth hormone-releasing factor-stimulated growth hormone secretion in the rat. (1992) (82)
Intensified rates of venous sampling unmask the presence of spontaneous, high-frequency pulsations of luteinizing hormone in man. (1984) (81)
Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. (1994) (80)
The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. (2001) (80)
Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. (1992) (79)
Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. (1996) (79)
Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I. (1998) (78)
A potential code of luteinizing hormone-releasing hormone-induced calcium ion responses in the regulation of luteinizing hormone secretion among individual gonadotropes. (1991) (77)
Differential tyrosine phosphorylation of JAK1, JAK2, and STAT1 by growth hormone and interferon-gamma in IM-9 cells. (1994) (76)
Bromocriptine. A clinical and pharmacological review. (1980) (76)
Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. (1982) (75)
Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man. (1985) (75)
Alpha and luteinizing hormone beta subunit messenger ribonucleic acids during the rat estrous cycle. (1986) (74)
Growth hormone release in response to human pancreatic tumor growth hormone-releasing hormone-40 in children with short stature. (1984) (74)
Human pancreatic tumor growth hormone (GH) - releasing factor and cyclic adenosine 3',5'- monophosphate evoke GH release from anterior pituitary cells: the effects of pertussis toxin, cholera toxin, forskolin, and cycloheximide. (1984) (74)
Growth hormone and nutrition. (1992) (73)
The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic–pituitary disease (1998) (73)
Relationship between growth hormone (GH) status, serum leptin and body composition in healthy and GH deficient elderly subjects (1997) (72)
Follicle-stimulating hormone- and alpha-subunit-secreting pituitary tumor treated with bromocriptine. (1985) (72)
Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. Intermittent secretion or response attenuation. (1984) (71)
Blunted growth hormone (GH) response to GH-releasing hormone in hypothyroidism resolves in the euthyroid state. (1985) (71)
Pregnancy in patients presenting with hyperprolactinaemia. (1979) (70)
Therapeutic controversy : Management of prolactinomas (1997) (69)
Pituitary adenomas producing growth hormone, prolactin, and one or more glycoprotein hormones: a histologic, immunohistochemical, and ultrastructural study of four surgically removed tumors. (1983) (69)
Comparison of competitive radioimmunoassays and two-site sandwich assays for the measurement and interpretation of plasma ghrelin levels. (2010) (68)
The pharmacokinetics of acyl, des-acyl, and total ghrelin in healthy human subjects. (2013) (67)
Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. (1997) (67)
Immunohistological localization of growth hormone-releasing hormone in human tumors. (1985) (67)
Long-term Infusion of Growth Hormone Release Inhibiting Hormone in Acromegaly: Effects on Pituitary and Pancreatic Hormones (1974) (67)
Stimulation of tyrosine phosphorylation in human cells by activation of the growth hormone receptor. (1993) (66)
Fasting alters pulsatile and rhythmic cortisol release in normal man. (1989) (65)
Human pancreatic growth hormone-releasing factor-40 (hpGRF-40) allows stimulation of GH release by TRH. (1983) (65)
Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback. (1997) (64)
Acceleration of Growth Rate in Growth Hormone-Deficient Children Treated with Human Growth Hormone-Releasing Hormone (1988) (64)
Sleep, awakenings, and insulin-like growth factor-I modulate the growth hormone (GH) secretory response to GH-releasing hormone. (1992) (63)
Selective growth hormone and cyclic AMP stimulating activity is present in human pancreatic islet cell tumor. (1982) (63)
Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man. (1984) (63)
Physiological role of somatostatin on growth hormone regulation in humans. (1990) (62)
Impact of intensive venous sampling on characterization of pulsatile GH release. (1987) (61)
Impact of the GH-cortisol ratio on the age-dependent changes in body composition. (2002) (60)
Leptin does not mediate short-term fasting-induced changes in growth hormone pulsatility but increases IGF-I in leptin deficiency states. (2008) (60)
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. (2008) (59)
Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation. (1991) (58)
The orphan receptor Gpr83 regulates systemic energy metabolism via ghrelin-dependent and ghrelin-independent mechanisms (2013) (58)
Effects of human pancreatic growth hormone-releasing factor-40 on serum growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and somatomedin-C concentrations in normal women throughout the menstrual cycle. (1984) (58)
Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy. (1989) (58)
Double Pituitary Lesions in Three Patients with Cushing's Disease (2000) (57)
Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults--a clinical research center study. (1996) (56)
Effects of gonadal steroids on somatotroph function in the rat: analysis by the reverse hemolytic plaque assay. (1988) (55)
Growth hormone release inhibiting hormone: actions on thyrotrophin and prolactin secretion after thyrotrophinreleasing hormone. (1975) (55)
Dopaminergic mechanisms and luteinizing hormone (LH) secretion. II. Differential effects of dopamine and bromocriptine on LH release in normal women. (1981) (55)
Letter: Metaclopramide and prolactin. (1974) (55)
AutoDecon: a robust numerical method for the quantification of pulsatile events. (2009) (55)
Human pancreatic tumor growth hormone-releasing factor stimulates anterior pituitary adenylate cyclase activity, adenosine 3',5'-monophosphate accumulation, and growth hormone release in a calmodulin-dependent manner. (1984) (54)
The GOAT-Ghrelin System Is Not Essential for Hypoglycemia Prevention during Prolonged Calorie Restriction (2012) (53)
Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men. (1985) (53)
Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH. (1986) (53)
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. (1996) (52)
Beta-adrenergic stimulation of growth hormone release from perifused rat anterior pituitary cells. (1983) (52)
MOLECULAR ABERRATION IN PLATELET MONOAMINE OXIDASE IN SCHIZOPHRENIA (1975) (52)
Acylated ghrelin concentrations are markedly decreased during pregnancy in mothers with and without gestational diabetes: relationship with cholinesterase. (2009) (51)
Cranial irradiation and growth hormone neurosecretory dysfunction: a critical appraisal. (2007) (51)
Impact of abdominal visceral fat, growth hormone, fitness, and insulin on lipids and lipoproteins in older adults. (2003) (50)
Protection against the synaptic targeting and toxicity of Alzheimer's‐associated Aβ oligomers by insulin mimetic chiro‐inositols (2013) (50)
The aging population--is there a role for endocrine interventions? (2009) (49)
Growth hormone, 1988. (1988) (49)
Growth hormone-releasing factor stimulation test in depression. (1988) (49)
Growth hormone-releasing factor (GRF) regulates expression of its own receptor. (1996) (48)
Muscle mechano growth factor is preferentially induced by growth hormone in growth hormone‐deficient lit/lit mice (2004) (48)
Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome (2004) (47)
Circulating growth hormone forms after stimulation of pituitary secretion with growth hormone-releasing factor in man. (1984) (47)
The diagnosis of growth hormone deficiency (GHD) in adults. (1995) (47)
Tissue-specific regulation of growth hormone (GH) receptor and insulin-like growth factor-I gene expression in the pituitary and liver of GH-deficient (lit/lit) mice and transgenic mice that overexpress bovine GH (bGH) or a bGH antagonist. (2004) (47)
Prolactin secretion in Parkinson disease (1981) (46)
The dynamics of growth hormone (GH) secretion in adult cancer survivors with severe GH deficiency acquired after brain irradiation in childhood for nonpituitary brain tumors: evidence for preserved pulsatility and diurnal variation with increased secretory disorderliness. (2005) (46)
Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man. (1978) (46)
Liver X Receptor Agonists Augment Human Islet Function through Activation of Anaplerotic Pathways and Glycerolipid/Free Fatty Acid Cycling* (2009) (45)
Growth hormone secretagogue receptor expression in human pituitary tumors. (1998) (45)
Statement by the Growth Hormone Research Society on the GH/IGF-I axis in extending health span. (2009) (45)
Plasma transport of human growth hormone in vivo. (1990) (44)
Selective beta 1-adrenergic receptor-blockade with atenolol enhances growth hormone releasing hormone and mediated growth hormone release in man. (1987) (44)
Intranasal administration of human pancreatic tumor GH-releasing factor-40 stimulates GH release in normal men. (1983) (44)
Evaluation of pulsatile patterns of growth hormone release in humans: A brief review (1993) (44)
Age-dependent decline in acyl-ghrelin concentrations and reduced association of acyl-ghrelin and growth hormone in healthy older adults. (2014) (44)
Effects of in vivo gonadal hormone environment on in vitro hGRF-40-stimulated GH release. (1985) (44)
Preservation of growth hormone pulsatility despite pituitary pathology, surgery, and irradiation. (1997) (43)
The role of ghrelin in GH secretion and GH disorders (2011) (43)
The Effects of Hyperprolactinemia on Sexual and Reproductive Function in Men (1981) (43)
Influence of matrix on concentrations of somatotropin measured in serum with commercial immunoradiometric assays. (1989) (43)
Physiological and clinical studies of GRF and GH. (1986) (42)
Sex-related differences in GH secretion in rat using reverse hemolytic plaque assay. (1986) (42)
Zinc may have a physiological role in regulating pituitary prolactin secretion. (1983) (42)
Performance of LH pulse-detection algorithms at rapid rates of venous sampling in humans. (1984) (41)
Treatment of prolactinomas. (1983) (41)
The Mutant Growth Hormone-Releasing Hormone (GHRH) Receptor of the Little Mouse Does Not Bind GHRH1. (1999) (41)
Dopaminergic mechanisms and luteinizing hormone secretion. I. Acute administration of the dopamine agonist bromocriptine does not inhibit luteinizing hormone release in hyperprolactinemic women. (1980) (40)
Acute peripheral metabolic effects of intraarterial ghrelin infusion in healthy young men. (2011) (39)
Comprehensive clinical endocrinology (2002) (39)
Fluorescence activated cell sorting of functional anterior pituitary cells. (1982) (39)
Erratum: Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study (Journal of Clinical Endocrinoloy and Metabolism (1995) 80 (2768-2775)) (1995) (39)
Contemporary tools for the analysis of episodic growth hormone secretion and clearance in vivo. (1988) (39)
Chapter 14 – Prolactin: Clinical Physiology and the Significance and Management of Hyperprolactinemia (1977) (39)
Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults (2008) (38)
Modified alternate‐day fasting regimens reduce cell proliferation rates to a similar extent as daily calorie restriction in mice (2008) (38)
The ghrelin axis in disease: Potential therapeutic indications (2011) (38)
Pituitary Response to Growth Hormone–Releasing Hormone in IDDM: Abnormal Responses to Insulin and Hyperglycemia (1992) (38)
Growth hormone-releasing hormone receptor mRNA in acromegalic pituitary tumors. (1997) (38)
The somatotrope: an endocrine cell with functional calcium transients. (1988) (37)
Pulsatile growth hormone secretion in older persons is enhanced by fasting without relationship to sleep stages. (1996) (37)
Pulsatile growth hormone secretion persists in genetic growth hormone-releasing hormone resistance. (2002) (37)
Growth hormone exerts acute vascular effects independent of systemic or muscle insulin-like growth factor I. (2008) (37)
Actions of estradiol on discrete attributes of the luteinizing hormone pulse signal in man. Studies in postmenopausal women treated with pure estradiol. (1987) (36)
Biphasic luteinizing hormone secretion in response to gonadotropin-releasing hormone during continuous perifusion of dispersed rat anterior pituitary cells: changes in total release and the phasic components during the estrous cycle. (1983) (35)
The self-priming effect of gonadotropin-releasing hormone on luteinizing hormone release: observations using rat anterior pituitary fragments and dispersed cells continuously perifused in parallel. (1984) (35)
Beta-adrenergic binding and secretory responses of the anterior pituitary. (1985) (35)
Growth hormone (GH) response to GH-releasing hormone in children with subnormal integrated concentrations of GH. (1986) (35)
The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients (2001) (34)
The mutant growth hormone-releasing hormone (GHRH) receptor of the little mouse does not bind GHRH. (1999) (33)
Acromegaly--results of long term treatment with bromocriptine. (1978) (33)
Periodic interactions of GH-releasing factor and somatostatin can augment GH release in vitro. (1987) (33)
A persistent pattern of varying pituitary responsivity to exogenous growth hormone (GH)-releasing hormone in GH-deficient children: evidence supporting periodic somatostatin secretion. (1988) (32)
Pancreatic endocrine tumour producing growth hormone-releasing hormone associated with multiple endocrine neoplasia type I syndrome. (1987) (32)
Assignment of the human growth hormone-releasing hormone receptor gene (GHRHR) to 7p14 by in situ hybridization. (1994) (32)
[28] Assay of growth hormone-releasing factor (1986) (32)
Correlation between GH and IGF-1 during treatment for acromegaly. (2016) (31)
Human growth hormone (GH) receptor is characterized as the 134-kilodalton tyrosine-phosphorylated protein activated by GH treatment in IM-9 cells. (1993) (31)
Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion. (1989) (31)
Ghrelin and growth hormone: Story in reverse (2010) (30)
A case of ectopic ACTH syndrome: diagnostic difficulties caused by intermittent hormone secretion. (1982) (30)
Follicle-Stimulating Hormone-Secreting Pituitary Tumor with Concomitant Elevation of Serum α-Subunit Levels* (1984) (29)
Divergent influences of the structurally dissimilar calcium entry blockers, diltiazem and verapamil, on thyrotropin- and gonadotropin-releasing hormone-stimulated anterior pituitary hormone secretion in man. (1985) (29)
A Case for Conservative Management: Characterizing the Natural History of Radiographically Diagnosed Rathke Cleft Cysts. (2015) (28)
High plasma growth hormone (GH) levels inhibit expression of GH secretagogue receptor messenger ribonucleic acid levels in the rat pituitary. (2000) (28)
Circulating microRNA as a biomarker of human growth hormone administration to patients. (2014) (28)
Molecular cloning of ovine and bovine growth hormone-releasing hormone receptors: the ovine receptor is C-terminally truncated. (2001) (28)
Continuous perifusion of dispersed anterior pituitary cells: technical aspects. (1983) (28)
Hormonal regulation of growth (1989) (28)
Malignant prolactinomas. Comment (1991) (27)
Hormone pulsatility discrimination via coarse and short time sampling. (1999) (27)
Chapter 15 AutoDecon (2009) (27)
Photoaffinity cross-linking to the pituitary receptor for growth hormone-releasing factor. (1994) (27)
Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors (2020) (27)
Growth Hormone‐Releasing Hormone and Growth Hormone‐Releasing Peptide as Potential Therapeutic Modalities (1990) (27)
Human growth hormone : research and clinical practice (2000) (26)
Digital Vasospasm with Bromocriptine (1976) (26)
Cranially irradiated adult cancer survivors may have normal spontaneous GH secretion in the presence of discordant peak GH responses to stimulation tests (compensated GH deficiency) (2009) (25)
LH release is facilitated by agents that alter cyclic AMP-generating system. (1984) (25)
Reversible sellar enlargement due to growth hormone‐releasing hormone production by pancreatic endocrine tumors in an acromegalic patient with multiple endocrine neoplasia type I syndrome (1988) (25)
Human pancreatic GRF stimulates phosphatidylinositol labeling in cultured anterior pituitary cells. (1983) (24)
The pharmacokinetics of bromocriptine in man. (1980) (24)
Chronic Changes in Peripheral Growth Hormone Levels Do Not Affect Ghrelin Stomach mRNA Expression and Serum Ghrelin Levels in Three Transgenic Mouse Models (2004) (24)
Endocrine impact of pure estradiol replacement in postmenopausal women: alterations in anterior pituitary hormone release and circulating sex steroid hormone concentrations. (1986) (24)
Ca+2 dependence of gonadotropin-releasing hormone-stimulated luteinizing hormone secretion: in vitro studies using continuously perifused dispersed rat anterior pituitary cells. (1983) (24)
Growth-hormone-releasing factor. (1983) (24)
Biological activity of a growth hormone-releasing factor secreted by a human tumor. (1983) (23)
Chronic estrogen treatment in male rats reveals mammosomatotropes and allows inhibition of prolactin secretion by somatostatin. (1996) (23)
The influence of anatomical boundaries, age, and sex on the assessment of abdominal visceral fat. (1997) (23)
The effect of intravenous, subcutaneous, and intranasal GH‐RH analog, [Nle27]GHRH(1–29)‐NH2, on growth hormone secretion in normal men: Dose‐response relationships (1986) (23)
Growth hormone induces tyrosine phosphorylation but does not alter insulin-like growth factor-I gene expression in human IM9 lymphocytes. (1994) (23)
Effect of obesity and feeding on the growth hormone (GH) response to the GH secretagogue L-692,429 in young men. (1997) (23)
Medianosomes as integrative units in the external layer of the median eminence. Studies on grf/catecholamine and somatostatin/catecholamine interactions in the hypothalamus of the male rat (1986) (22)
Absence of uterine neoplasia in patients on bromocriptine. (1977) (22)
Pergolide mesylate: its effects on circulating anterior pituitary hormones in man. (1981) (22)
1 Disorders of prolactin and growth hormone secretion (1985) (22)
Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. (1998) (22)
Motilin-related peptide and ghrelin: lessons from molecular techniques, peptide chemistry, and receptor biology. (2001) (21)
Hyperprolactinemia: current concepts of management including medical therapy with bromocriptine. (1980) (21)
Bromocriptine in the medical management of acromegaly. (1980) (21)
Pituitary self-priming actions of gonadotropin-releasing hormone. Kinetics of estradiol's potentiating effects on gonadotropin-releasing hormone-facilitated luteinizing hormone and follicle-stimulating hormone release in healthy postmenopausal women (1986) (20)
The discovery of growth hormone-releasing hormone. (1999) (20)
Cushing's syndrome from the therapeutic use of intramuscular dexamethasone acetate. (1986) (20)
Growth Hormone Releasing Hormone and Growth Hormone: Genetic Studies in Familial Growth Hormone Deficiency (1985) (20)
Urinary growth hormone (GH), insulin-like growth factor I (IGF-I), and IGF-binding protein-3 measurements in the diagnosis of adult GH deficiency. (1998) (20)
Cytosolic free calcium in normal somatotropes: effects of forskolin and phorbol ester. (1989) (19)
The somatotrophic axis and the reproductive process in health and disease. (1994) (19)
Cross-linking of a growth hormone releasing factor-binding protein in anterior pituitary cells. (1986) (19)
The impact of short-term fasting on the dynamics of 24-hour growth hormone (GH) secretion in patients with severe radiation-induced GH deficiency. (2006) (19)
Effects of glucose and insulin on acyl ghrelin and desacyl ghrelin, leptin, and adiponectin in pregnant women with diabetes. (2010) (19)
Cloning of the chicken pituitary receptor for growth hormone-releasing hormone. (2006) (19)
Dopaminergic Mechanisms and Luteinizing Hormone (LH) Secretion (1982) (18)
Calcium channel agonist BAY k8644 enhances anterior pituitary secretion in rat and monkey. (1985) (18)
Association of plasma des-acyl ghrelin levels with CKD. (2013) (18)
Bromocriptine treatment of hyperprolactinaemic hypogonadism. (1978) (18)
Prolactin and psychophysiologic measures after single doses of thioridazine (1977) (18)
SERUM PROLACTIN AND OESTRADIOL LEVELS AT DIFFERENT STAGES OF PUBERTY (1977) (17)
Clinical studies with GHRH in man. (1986) (17)
BROMOCRIPTINE-RESPONSIVE FORM OF IDIOPATHIC ŒDEMA (1979) (17)
Sex Differences in β-Adrenergic Stimulation of Growth Hormone Secretion in Vitro (1986) (17)
Genetic differences in the IGF-I gene among inbred strains of mice with different serum IGF-I levels. (2005) (16)
The Role of Brain Dopamine (1989) (15)
Gonadotropin-Releasing Hormone-Stimulated Phosphoinositide Hydrolysis in the Anterior Pituitary (1988) (15)
Growth hormone response to growth hormone releasing factor in Alzheimer's disease. (1989) (15)
Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study* (2018) (15)
Ectopic pituitary gland simulating a suprasellar tumor. (1987) (14)
Growth hormone and prolactin responses to bolus and sustained infusions of GRH-1-40-OH in man (1987) (14)
ANNIVERSARY REVIEW: 50 years since the discovery of bromocriptine. (2018) (14)
Somatoliberinoma: morphologic characteristics. (1984) (14)
Atenolol enhances nocturnal growth hormone (GH) release in GH-deficient children during long term GH-releasing hormone therapy. (1990) (14)
Morphologic effects of bromocriptine on spontaneously occurring pituitary prolactin-cell hyperplasia in old Long-Evans rats. (1986) (14)
Growth hormone supplementation in the elderly. (2007) (13)
Ghrelin, not just another growth hormone secretagogue (2001) (13)
Prolactin and gonadal function. (1981) (13)
Bromocriptine in acromegaly. (1981) (13)
Neuroendocrine regulation of growth hormone secretion (1995) (13)
Metabolic Benefit of Chronic Caloric Restriction and Activation of Hypothalamic AGRP/NPY Neurons in Male Mice Is Independent of Ghrelin. (2016) (12)
Controversy: radiotherapy for acromegaly (2003) (12)
Spontaneous sparsely-granulated prolactin-producing pituitary adenomas in aging rats. A prospective study of the effect of bromocriptine. (1985) (12)
Therapeutic Applications of Bromocriptine in Endocrine and Neurological Diseases (1988) (12)
Purification of the growth hormone releasing hormone receptor with a C-terminal, biotinylated affinity ligand. (1996) (12)
Luteinizing hormone secretion is enhanced by pertussis toxin, cholera toxin, and forskolin. Evidence for the involvement of the cyclic AMP-generating system. (1983) (11)
Life extension versus improving quality of life. (2004) (11)
Bromocriptine in the treatment of the hyperprolactinaemia-hypogonadism syndromes. (1976) (11)
Unremitting suppression of the postovariectomy rise in plasma LH by tumor-induced hyperprolactinemia. (1982) (11)
ANALOGUES OF GROWTH-HORMONE RELEASE-INHIBITING HORMONE (1975) (11)
Mechanisms for Hypogonadism in Hyperprolactinemia (1984) (11)
Regulation of full-length and truncated growth hormone (GH) receptor by GH in tissues of lit/lit or bovine GH transgenic mice. (2004) (10)
Clinical Endocrinology 6 Metabolism Editor-in-chief: Delbert A. Fisher (10)
IGF-I does not affect the net increase in GH release in response to arginine. (2002) (10)
Development of a Predictive Enrichment Marker for the Oral GH Secretagogue LUM-201 in Pediatric Growth Hormone Deficiency (2021) (10)
On the discovery of growth hormone‐releasing hormone (1993) (10)
Growth hormone insensitivity and obesity: Insights from human and animal models. (2009) (9)
Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. (2005) (9)
Human studies of growth hormone and aging. (2007) (9)
Serum adrenal androgens in hyperprolactinaemic women prior to, during, and after chronic treatment with bromocriptine (1982) (9)
Hexarelin Modulates the Expression of Growth Hormone Secretagogue Receptor Type 1a mRNA at Hypothalamic and Pituitary Sites (2004) (8)
Assay of growth hormone-releasing factor. (1986) (8)
The intestinal lymph fistula model--a novel approach to study ghrelin secretion. (2010) (8)
One minute of bromocriptine irreversibly inhibits prolactin release for hours. (1984) (8)
Lack of contribution of 11betaHSD1 and glucocorticoid action to reduced muscle mass associated with reduced growth hormone action. (2004) (8)
Decrease of Serum IGF-I following Transsphenoidal Pituitary Surgery for Acromegaly. (2017) (7)
Development of antibody to growth hormone-releasing factor. (1985) (7)
LEAP 2 changes with body mass and food intake in humans and mice (2019) (7)
The level of circulating octanoate does not predict ghrelin O-acyl transferase (GOAT)-mediated acylation of ghrelin during fasting. (2015) (7)
Cytokines in endocrine function. (1998) (7)
Diurnal variation in growth hormone receptor messenger ribonucleic acid in liver and skeletal muscle of lit/+ and lit/lit mice. (2004) (7)
Ionophore bromo-A23187 reveals cellular calcium stores in single pituitary somatotropes (1989) (7)
Serum prolactin and oestradiol levels at different stages of puberty. (1978) (7)
Growth hormone increases mRNA levels of PPARdelta and Foxo1 in skeletal muscle of growth hormone deficient lit/lit mice. (2009) (6)
Ghrelin in Health and Disease (2012) (6)
Recombinant Human Leptin Does Not Alter Gut Hormone Levels after Gastric Bypass but May Attenuate Sweet Cravings (2014) (6)
Acromegaly and Serum Insulin-Like Growth Factor I (2005) (6)
SMS 201-995: Studies in Acromegaly and in Normal Menxs (1986) (5)
Luminal influences to orchestrate gastroenterological hormone secretion: the fat, long-chain Fatty Acid, cholecystokinin, glucagon-like Peptide 1 axis. (2010) (5)
Chapter 12 – Therapeutic Implications of Dopaminergic Drugs in Acromegaly (1977) (5)
Proceedings: The relationship between prolactin and gonadotrophins: effects of clomiphene administration in normal men. (1974) (5)
P-51 24-h mean acyl-ghrelin levels are decreased in older adults (2008) (5)
Letter: Antiemetics, prolactin, and breast cancer. (1974) (5)
Clinical Neuroendocrine Relationships in Normal and Disordered Prolactin Secretion (1979) (5)
Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. (1998) (5)
Prolactin secretion as an index of brain dopaminergic function. (1981) (5)
Disorders of prolactin and growth hormone secretion. (1985) (5)
Corroboration of Height Velocity Prediction Markers for rhGH With an Oral GH Secretagogue Treatment in Children With GHD (2021) (5)
Growth hormone releasing factor and somatomedin C production: extrahypothalamic localization and possible functional significance. (1986) (5)
Mesulergine, a new dopamine agonist: Effects on anterior pituitary function and kinetics (1984) (5)
Human Growth Hormone (2000) (5)
Prokaryotic adenylate cyclase toxin stimulates anterior pituitary cells in culture. (1986) (4)
Preoperative diagnosis of acromegaly by growth hormone-releasing factor radioimmunoassay. (1991) (4)
Pituitary response to intravenous hypothalamic releasing peptides in cynomolgus monkeys treated with contraceptive steroids. (1987) (4)
Caloric restriction in mTORC1 control of intestinal homeostasis. (2012) (4)
State-of-the-art strategies for the diagnosis and management of acromegaly (2001) (4)
Follicle-stimulating hormone-secreting pituitary tumor with concomitant elevation of serum alpha-subunit levels. (1984) (4)
Predictors of Growth Hormone Secretion in Aging (2000) (4)
Growth Hormone Safety Workshop Position Paper: a (2015) (4)
Age and Sex-Related Neurosecretion of Growth Hormone (1988) (4)
Successful treatment of acromegaly with bromocriptine. (1976) (4)
STUDIES ON THE MECHANISMS OF THE DOPAMINE-MEDIATED INHIBITION OF PROLACTIN SECRETION (1981) (4)
Differential effects of forskolin on LH and GH release. (1985) (4)
Clinical Aspects of Dopamine in the Regulation of Human Anterior Pituitary Function (1989) (4)
Four-hour infusion of hydrocortisone does not suppress the nocturnal increase of circulating acyl- or desacyl-ghrelin concentrations in healthy young adults. (2014) (4)
Growth Hormone Economy in Normally Cycling Women (1995) (4)
Serum adrenal androgens in hyperprolactinaemic women prior to, during, and after chronic treatment with bromocriptine. (1983) (4)
Growth Hormone Replacement Therapy in Adult Onset GH Deficiency : Effects on Body Composition in Men and Women in a Double-Blind , Randomized , Placebo-Controlled Trial (2005) (3)
Bromocriptine therapy for prolactin-secreting pituitary adenomas. (1996) (3)
The Physiology of Human Growth: Growth hormone and growth hormone releasing hormone (1989) (3)
21 – HYPERPROLACTINAEMIA AND OVULATION (1978) (3)
Growth hormone response to growth hormone-releasing factor in depression (1988) (3)
Quantification of growth hormone mRNA in blood. (2012) (3)
The orphan receptor GPR83 regulates systemic energy metabolism via ghrelin-dependent and -independent mechanisms (2013) (3)
The research community now and in the future: APM's recommendations for NIH priorities. (2003) (3)
The dynamics of GH secretion in adult cancer survivors with severe radiation-induced GH deficiency (2005) (3)
Therapeutic agents produced by genetic engineering: Quo vadis? The example of growth hormone and its releasing factor. Satellite symposium. Toulouse-Labège, May 29-30, 1985. (1986) (3)
Changes in the anatomy and function of the maternal anterior pituitary gland during pregnancy. (1990) (3)
Effects of hyperprolactinemia and bromocriptine on the human endometrium. (1981) (3)
Bromocriptine and endocrine disorders. (1979) (3)
Spatiotemporal Regulation of Insulin-Like Growth Factor-1 and Its Receptor in the Brain: Is There a Role for Growth Hormone? (2017) (3)
Book Review: Prolactin and Human Reproduction (1978) (3)
Growth-hormone-releasing hormone: a clinical update. (1986) (2)
DOPAMINE AND INHIBITION OF PROLACTIN AND GROWTH-HORMONE SECRETION (1976) (2)
Letter: Digital vasospasm with bromocriptine. (1976) (2)
Endocrinology of Aging: The Convergence of Reductionist Science with Systems Biology and Integrative Medicine (2010) (2)
Chemical, Anatomical, and Physiological Studies on Human Pancreatic and Rat Hypothalamic Growth Hormone-Releasing Factor (1986) (2)
Some clinical considerations of growth hormone and growth hormone-releasing hormone (1988) (2)
EFFECT OF A SINGLE BOUT OF EXERCISE ON 4-h AND 24-h GROWTH HORMONE (GH) RELEASE IN YOUNG AND OLDER SUBJECTS (1998) (2)
Sex differences in beta-adrenergic stimulation of growth hormone secretion in vitro. (1986) (2)
Pituitary self-priming actions of gonadotropin-releasing hormone. Kinetics of estradiol's potentiating effects on gonadotropin-releasing hormone-facilitated luteinizing hormone and follicle-stimulating hormone release in healthy postmenopausal women. (1987) (2)
Sandostatin ® (SMS 201–995) in the Treatment of Acromegaly (1988) (2)
Clinical Biochemistry and Endocrinology—The Future (1974) (2)
Drugs Five Years Later (2020) (2)
Dopamine and bromocriptine inhibit cyclic AMP accumulation in the anterior pituitary: the effect of cholera toxin. (1982) (2)
Correlation study of serum prolactin levels, pituitary weights, number and ultrastructure of pituitary lactotrophs in female Long-Evans rats. (1990) (2)
Hyperprolactinaemic infertility: some considerations on medical management (1984) (2)
Octreotide Treatment of Acromegaly (2020) (1)
Growth Hormone Releasing Hormone and Growth Hormone Releasing Peptides (1995) (1)
TREATMENT WITH ATENOLOL INCREASES THE GROWTH HORMONE (GH) RESPONSE TO EXOGENOUS GH RELEASING HORMONE (GHRH) BUT FAILS TO AUGMENT ENDOGENOUS GH SECRETION IN NON–GH DEFICIENT SHORT BOYS (1987) (1)
A GH Secretagogue Receptor Agonist (LUM-201) Elicits Greater GH Responses than Standard GH Secretagogues in Subjects of a Pediatric GH Deficiency Trial (2022) (1)
Disorders of prolactin secretion. (1976) (1)
Ghrelin Receptor Agonists in Cachexia of Human Aging (2012) (1)
50 years since the discovery of bromocriptine (2018) (1)
Regulation of Growth Hormone and Action (Secretagogues) (2010) (1)
ESTIMATION OF ABDOMINAL VISCERAL FAT (AVF) IN MEN AND WOMEN 1378 (1997) (1)
Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. (1982) (1)
GASTROINTESTINAL BLEEDING IN PATIENTS ON BROMOCRIPTINE (1976) (1)
The Discovery of Growth Hormone‐Releasing Hormone 1 (2008) (1)
Growth Hormone: Normal Physiology (1997) (1)
Does low-dose growth hormone therapy improve the body composition of patients infected with HIV? (2009) (1)
ENDOCRINE EFFECTS OF DOPAMINERGIC ERGOT ALKALOIDS — TOXICOLOGICAL IMPLICATIONS (1979) (1)
Dietary macronutrient regulation of acyl and desacyl ghrelin concentrations in children with Prader‐Willi syndrome (PWS) (2020) (1)
Subject Index Vol. 31, 1980 (1980) (1)
Does des-acyl ghrelin improve glycemic control by decreasing acylated ghrelin levels? (2015) (1)
LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency (2021) (0)
Growth Hormone: A Current Perspective (1995) (0)
Actions of GRF in Man (1987) (0)
Clinical uses of growth hormone releasing peptides (GHRPs) and GHRP analogues in adults (2000) (0)
Abstracts of Selected Free Communications (1986) (0)
Hollow Fibers: Their Applications to the Study of Mammalian Cell Function (1984) (0)
Society for Endocrinology Dale Medal Lecture (2009) (0)
SOMATOSTATIN (SS) SECRETORY RHYTHM IN GROWTH HORMONE RELEASING HORMONE (GHRH)–DEFICIEST CHILDREN (1987) (0)
Primary therapy with somatostatin analogues in acromegaly does not restore orderly GH secretion (2004) (0)
Response of cytosolic free calcium concentration and membrane potential to somatostatin and dopamine: a study in individual pituitary somatotropes and lactotropes (1989) (0)
Letter: Dopamine and inhibition of prolactin and growth-hormone secretion. (1976) (0)
Growth Hormone Releasing Hormone: Therapeutic Potentials (1987) (0)
Placebo-Controlled Trial Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Growth Hormone (GH) Replacement Therapy in Adult-Onset GH Deficiency: (2004) (0)
GROWTH HORMONE (GH) RELEASE IN CHILDREN WITH SHORT STATURE: STIMULATION BY HUMAN PANCREATIC TUMOR GROWH HORMONE RELEASING FACTOR-40 (hpGRF-40) (1984) (0)
Title: The Pharmacokinetics of Acyl, Desacyl and Total Ghrelin in Healthy Human (2013) (0)
Answering your questions about sexual medicine (1982) (0)
OR07-1 Circulating RNAs as markers of growth hormone doping (2012) (0)
Gonadotropin-releasing hormone-stimulated phosphoinositide hydrolysis in the anterior pituitary. Modulation by protein kinase C but not by cyclic nucleotides. (1988) (0)
RAPID GLUCAGON RELEASE IN ARTIFICIAL FEVER (1974) (0)
A young man with visual defect and galactorrhea. (1982) (0)
BODY DENSITY DETERMINATION BY HYDROSTATIC WEIGHING AND AIR DISPLACEMENT PLETHYSMOGRAPHY IN CHILDREN AND ADULTS (1999) (0)
Contents, Vol. 31, 1980 (1980) (0)
DIMINISHED PULSATILE LUTEINIZING HORMONE SECRETION AND SUPERSENSITIVITY TO GONADOTROPIN RELEASING HORMONE IN AMENORRHEIC RUNNERS (1984) (0)
OR2,11 Evidence in support of luminal versus circulating octanoate for ghrelin O-acyl transferase (GOAT)-mediated acylation of ghrelin (2010) (0)
Letter: Analogues of growth-hormone release-inhibiting hormone. (1975) (0)
Growth-Hormone-Releasing Factor: Clinical Considerations (1987) (0)
WILLIAM PARSON: 1926–2004 (2006) (0)
CHARACTERIZATION OF CORTICOTROPIN AND GROWTH HORMONE RELEASING FACTOR. (1983) (0)
Effects of 7-day treatment with the orally active growth hormone (GH) secretagogue, MK-677, on insulin-like growth factor-I (IGF-I) levels, 24-hour GH and cortisol profiles, and sleep in normal young men (1996) (0)
Spontaneous GH secretion in the fed and fasting states in cranially irradiated adult cancer survivors with normal peak GH responses to two provocative tests: does GH neurosecretory dysfunction exist? (2006) (0)
Subject Index Vol. 37, 1983 (1983) (0)
Healthspan: how far can it be extended into aging? (2009) (0)
Letters to the Editor (0)
Comparisons in Various Populations Fat-Free Mass Predictions through a Bayesian Network Enable Body Composition (2015) (0)
Theodore R. Woodward Award. Age-related decline in growth hormone secretion: clinical significance and potential reversibility. (1997) (0)
Action of dopamine receptor agonists and antagonists, and a serotonin antagonist on prolactin release from isolated rat pituitary cell columns [proceedings]. (1979) (0)
The Endocrine Society 2013 Laureate Awards (2013) (0)
434 ENHANCED RESPONSE TO hpGRH-40 IN GROWTH HORMONE NEUROSECRETORY DYSFUNCTION (1985) (0)
Hypothalamic releasing hormones: clinical possibilities. (1986) (0)
CHAPTER 14 – New Dopamine Agonists in the Treatment of Hyperprolactinemia and Acromegaly (1981) (0)
OR01-3 GENOME MICROARRAY ANALYSIS OF THE IN VIVO EFFECTS OF A SINGLE DOSE OF GROWTH HORMONE ON VISCERAL FAT OF GH-DEFICIENT lit/lit MICE AND GH-SUFFICIENT lit/+ MICE (2006) (0)
SY1-6: Growth hormone and sarcopenia - future aspects (2014) (0)
Atlas of Endocrine Imaging (1993) (0)
Therapeutic Effects of Growth Hormone Releasing Hormone (1988) (0)
Contents, Vol. 37, 1983 (1983) (0)
Discordant stimulated growth hormone (GH) responses in cranially irradiated adult cancer survivors may occur in the presence of normal GH status: compensated GH deficiency (2008) (0)
William Parson: 1913-2002. (2006) (0)
The effect of bromocriptine on the mammary glands of hyperprolactinemic rats. A histologic, ultrastructural and morphometric study. (1984) (0)
Book Review The Pituitary Edited by Shlomo Melmed. 729 pp., illustrated. Cambridge, Mass., Blackwell Science, 1995. $150. 0-86542-126-9 (1995) (0)
Amenorrhea, depression and hypercortisolism. (1982) (0)
Citation for the 1998 Monsanto Clinical Investigator Award of the Endocrine Society to Dr. Cyril Y. Bowers. (1998) (0)
Clinical Aspects of Growth Hormone Hypersecretory States (1988) (0)
Isolation and characterization of hormone receptor that releases growth hormone. (1993) (0)
Separation and characterization of the growth hormone-releasing hormone receptor (1993) (0)
High Protein Meals Decrease the Ratio of Acyl and Desacyl Ghrelin to Peptide YY in Children with Prader‐Willi Syndrome (2015) (0)
Clinical Studies with Growth Hormone Releasing Hormone (1996) (0)
Sulpiride and lisuride interaction on prolactin release in humans (1985) (0)
Constitutive Activity of the ACTH Receptor: A Novel Cause of Adrenal Hyperplasia and a Novel Mechanism of Constitutive Activity (2003) (0)
EFFECTS OF METHOD, AGE AND GENDER ON THE ASSESSMENT OF INTRA-ABDOMINAL VISCERAL FAT BY COMPUTED TOMOGRAPHY 1159 (1996) (0)
Chapter 21 – Therapeutic Potential of GH Secretagogues in Adults (1999) (0)
Subject Index Vol. 50, 1989 (1989) (0)
Letter: Rapid glucagon release in artificial fever. (1974) (0)

This paper list is powered by the following services:

Other Resources About Michael O. Thorner

en.wikipedia.org

What Schools Are Affiliated With Michael O. Thorner?

Michael O. Thorner is affiliated with the following schools: